A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
This study is for people with advanced non-small cell lung cancer. Doctors want to see if a combination of two newer drugs, nivolumab and ipilimumab (which are types of immunotherapy), given alongside traditional chemotherapy, is more effective than just chemotherapy on its own. The main goal is to find out if this new combination helps patients live longer. Researchers will also look at how long people live without their cancer growing, and how much the tumours shrink. This is to see if adding these new drugs can improve treatment results for people with this type of lung cancer.
At a glance
What is this study about?
This research is looking for better ways to treat a type of lung cancer called Stage IV non-small cell lung cancer. 'Stage IV' means the cancer has spread from where it started to other parts of the body. Currently, chemotherapy is a common treatment, but doctors are always searching for options that work better or have fewer side effects.
This study combines standard chemotherapy with two newer drugs called nivolumab and ipilimumab. These drugs are a type of treatment known as immunotherapy. Immunotherapy works by helping your body's own immune system fight the cancer. The study is designed to compare people who get the new drug combination plus chemotherapy against those who only get chemotherapy. This helps doctors understand if the new combination is a more effective option.
The main thing the study wants to find out is if people live longer with the new treatment combination (this is called 'Overall Survival'). They will also keep an eye on other important things, like how long people live without their cancer getting worse ('Progression Free Survival'), and if their tumours shrink ('Overall Response Rate'). Researchers will also explore if different characteristics of the cancer cells, or changes in the genetic makeup of the tumour, affect how well the treatment works.
Key takeaways
- This study is for advanced non-small cell lung cancer.
- It tests a new combination of immunotherapy and chemotherapy.
- The main goal is to see if this combination helps people live longer.
- Participation involves regular hospital visits for treatment and checks.
- You might receive the new combination or standard chemotherapy.
- You can stop participating at any time.
Who may be eligible?
This study is for adults aged 18 years and older. Both men and women can take part.
To be considered for this study, you must have been diagnosed with Stage IV non-small cell lung cancer and be starting your very first treatment for it. The doctors will also check other things like your overall health and how well your body's organs are working to make sure it's safe for you to join the study.
There will be specific medical criteria that your doctor will need to review. For example, certain other health conditions, past treatments, or specific types of cancer might mean you can't join. Your medical team will carefully look at all your health information to see if this study is suitable for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have Stage IV non-small cell lung cancer?
- Are you starting your first treatment for this advanced lung cancer?
- Do you feel generally well enough to take part in a study?
- Are you able to attend regular appointments and receive infusions?
What does participation involve?
If you decide to take part, you would be randomly assigned to one of two groups, like flipping a coin. One group will receive chemotherapy along with the study drugs (nivolumab and ipilimumab), while the other group will receive chemotherapy on its own. You won't know which group you are in.
Your treatment will involve regular infusions, which means the medication is given through a drip into your arm, usually in a hospital or clinic setting. You will have a number of visits for these treatments and to have check-ups, blood tests, and scans to monitor your health and how the treatment is working. This will help the study doctors see if the treatment is helping your cancer. The duration of your participation will depend on how you respond to the treatment and the study plan, but it will involve ongoing follow-up for a period of time to track your health.
Potential risks and benefits
Locations (7)
- —UnverifiedSpain
- —UnverifiedIreland
- —UnverifiedPoland
- —UnverifiedBelgium
- —UnverifiedFrance
- —UnverifiedGermany
- —UnverifiedRomania
Common questions
What is immunotherapy?
Immunotherapy is a treatment that uses your body's own immune system to fight cancer.
What does 'Stage IV' cancer mean?
Stage IV means the cancer has spread from its original location to other parts of your body.
Will I get the new drugs if I join?
You have a chance of getting the new drugs plus chemotherapy, or just chemotherapy, chosen randomly.
How long will the treatment last?
The length of treatment will depend on how you respond and the study's plan.
Can I leave the study if I change my mind?
Yes, you can leave the study at any time, for any reason, without affecting your care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.